Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Cash (2017 - 2025)

Historic Change in Cash for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$146000.0.

  • Aclaris Therapeutics' Change in Cash fell 10058.83% to -$146000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.4 million, marking a year-over-year decrease of 36007.43%. This contributed to the annual value of -$15.3 million for FY2024, which is 18353.4% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Change in Cash of -$146000.0 as of Q3 2025, which was down 10058.83% from -$5.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Change in Cash's 5-year high stood at $78.2 million during Q2 2021, with a 5-year trough of -$59.8 million in Q3 2021.
  • Over the past 5 years, Aclaris Therapeutics' median Change in Cash value was -$555000.0 (recorded in 2023), while the average stood at $168052.6.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 46524.18% in 2021, then tumbled by 285429.59% in 2024.
  • Aclaris Therapeutics' Change in Cash (Quarter) stood at -$26.3 million in 2021, then soared by 37.62% to -$16.4 million in 2022, then soared by 105.12% to $838000.0 in 2023, then plummeted by 2854.3% to -$23.1 million in 2024, then surged by 99.37% to -$146000.0 in 2025.
  • Its last three reported values are -$146000.0 in Q3 2025, -$5.0 million for Q2 2025, and $5.8 million during Q1 2025.